DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Phase I Study of IPI-504 and Docetaxel in Patients With Advanced Solid Tumors

Information source: Infinity Pharmaceuticals, Inc.
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Solid Tumors

Intervention: IPI-504, docetaxel (Drug)

Phase: Phase 1

Status: Completed

Sponsored by: Infinity Pharmaceuticals, Inc.

Official(s) and/or principal investigator(s):
Gregory Riely, MD, Principal Investigator, Affiliation: Memorial Sloan Kettering Cancer Center


This study is a Phase I clinical trial of IPI-504 in combination with docetaxel (Taxotere).The purposes of the study are to determine:

- the safety profile,

- the highest dose of IPI-504 that can be given with docetaxel without causing severe

side effects, and

- to recommend a Phase II dose of the combination in patients with solid tumors.

Clinical Details

Official title: A Phase I Study of IPI-504 and Docetaxel in Patients With Advanced Solid Tumors

Study design: Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: To determine the safety, maximum tolerated dose(MTD)of IPI-504 in combination with docetaxel in patients with advanced solid tumors and recommend the Phase II dose of the combination of drugs.

Secondary outcome:

To determine the pharmacokinetics (PK) and response rate (CR+PR) for patients with measurable lesions (as determine by RECIST)

To determine the pharmacokinetics (PK) of IPI-504 and docetaxel

Detailed description: IPI-504 is a novel small molecule inhibitor of heat shock protein 90 (Hsp90), an emerging and recently identified target for cancer therapy. Hsp90 is a protein chaperone that plays a central role in maintaining the proper folding, function and viability of various "client proteins". Many of the client proteins stabilized by Hsp90 are oncoproteins and cell-signaling proteins important in cancer cell proliferation and cancer cell survival. This is a multi-center, open-label, dose escalating study in which patients will be treated with a fixed dose of docetaxel followed by IPI-504 following one of three dosing schedules. Once an MTD has been defined, up to 20 additional patients with non-small cell lung cancer (NSCLC) will be enrolled.


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- Pathologically confirmed malignancy that is metastatic or unresectable, for which one

of the two statements must apply:

- Standard therapy able to provide clinical benefit does not exist or is no

longer effective AND / OR

- Single agent docetaxel would be appropriate therapy.

- Progressive disease with development of new lesions or an increase in preexisting

lesions on CT, MRI, PET, bone scintigraphy, or by physical examination.

- Measurable disease by RECIST criteria with the exception of prostate cancer patients.

- >18 years of age at the time of signing the Informed Consent Form (ICF) and have a

life expectancy of at least 3 months.

- Karnofsky performance status of 70 or better.

- Adhere to the study visit schedule

- Voluntarily sign the Informed Consent Form (ICF).

- Baseline studies completed within 30 days of first study dose.

- Women of child-bearing potential (WCBP) defined as a sexually mature woman who has

not undergone a hysterectomy or who has not been naturally post-menopausal for at least 24 consecutive months must have a negative serum or urine pregnancy test within 2 weeks of first study dose and prior to each additional cycle of treatment.

- All WCBP and all sexually active male patients must agree to use adequate methods of

birth control throughout the study ** Non-small cell lung cancer (NSCLC)enrolled in the Expansion Phase of the study must meet the following additional inclusion criteria:

- NSCLC that meets the disease criteria described in the first three Inclusion


- Must have archival NSCLC tissue available for submission and analysis.

Exclusion Criteria:

- Treatment within 1 week of the start of IPI-504 for erlotinib, and imatinib; within 2

weeks for gefitinib, and any other tyrosine kinase inhibitor (approved or investigational); within 4 weeks for any biologic therapy (antibody, vaccine, or other protein-based therapy), radiation therapy, or conventional chemotherapy; within 6 weeks for nitrosoureas or mitomycin C.

- Radiation therapy within 2 weeks of the start of IPI-504. (Patients must have

recovered from any toxicities.)

- Concurrent radiation therapy or treatment with any other investigational agent is not


- Use of a medication or food that is a clinically relevant CYP3A inhibitor or inducer

within 2 weeks prior to Cycle 1, Dose 1.

- Symptomatic peripheral neuropathy ≥ Grade 2.

- Inadequate hematologic function defined by absolute neutrophil count (ANC) <1,500

cells/mm3, a platelet count <100,000/mm3, and a hemoglobin <9. 0 g/dL (may be increased to this level with transfusion as long as there is no evidence of active bleeding).

- Inadequate renal function defined by AST and/or ALT >1. 5; total bilirubin above the

upper limit of normal.

- Inadequate renal function defined by serum creatinine >1. 5 x ULN.

- Sinus bradycardia (resting heart rate <50) secondary to intrinsic conduction system

disease. Patients with sinus bradycardia secondary to pharmacologic treatment may enroll if withdrawal of the treatment results in normalization of the resting heart rate to within normal limits.

- Baseline QTc >450 msec in males; QTc >470 msec in females, or previous history of QT

prolongation while taking other medications.

- Presence of left bundle branch block, right bundle branch block plus left anterior

hemiblock, bifasicular block or 3rd degree heart block. This does not include patients with a history of these events with adequate control by pacemaker.

- Patients who have received >450 mg/m2 of any anthracycline during prior chemotherapy

must have a baseline LVEF >40%.

- Active keratitis or keratoconjunctivitis.

- History of severe hypersensitivity reaction to docetaxel or other drugs formulated

with polysorbate 80.

- Presence of active infection or systemic use of antibiotics within 72 hours of


- Untreated brain metastases. Note: Patients with a history of brain metastases are

eligible as long as definitive treatment has been given and patients are clinically stable.

- Significant co-morbid condition or disease which in the judgment of the Investigator

would place the patient at undue risk or interfere with the study (e. g., cardiac disease such as acute coronary syndrome or unstable angina within 6 months, uncontrolled hypertension, arrhythmia requiring medication or mechanical control, cirrhotic liver disease, or other conditions).

- Previous or current malignancies at other sites within the last 2 years, with

exception of adequately treated cone-biopsied in situ carcinoma of the cervix uteri and basal or squamous cell carcinoma of the skin.

- HIV-positive patients receiving combination antiretroviral therapy.

- Women who are pregnant or lactating.

- Previous treatment with 17-AAG, DMAG, or other known Hsp90 inhibitor.

- Patients with prior hepatic resection or hepatic-directed therapy (e. g.,

chemoembolization or Theresphere). **Patients with non-small cell lung cancer (NSCLC)enrolled in the Expansion Phase of the study must meet the following additional exclusion criteria:

- Prior treatment with docetaxel

- Three or more chemotherapy regimens for metastatic disease. Note: Any number of

prior treatment regimens with tyrosine kinase inhibitors is permitted.

Locations and Contacts

TGen Clinical Research in Scottsdale, Scottsdale, Arizona 85258, United States

Yale Cancer Center, New Haven, Connecticut 06519, United States

H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida 33612, United States

Roswell Park Cancer Institute, Buffalo, New York 14263, United States

Memorial Sloan-Kettering Cancer Center, New York City, New York 10066, United States

Gabrail Cancer Center, Canton, Ohio 44718, United States

Gabrail Cancer Center, Dover, Ohio 44622, United States

University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania 15232, United States

Additional Information

Starting date: December 2007
Last updated: March 2, 2012

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017